secwatch.observer — SEC 8-K summary
======================================

Issuer:     PURE BIOSCIENCE, INC. (PURE)
CIK:        0001006028
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001493152-23-044855
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PURE Bioscience Q1 revenue rises 54% to $718K; net loss narrows to $735K
------------------------------------------------------------------------

- Net product sales of $718K for Q1 FY2024, up $251K from $467K in Q1 FY2023.
- Net loss improved to $735K from $993K year-over-year; EPS unchanged at ($0.01).
- Excluding share-based compensation, net loss was $655K vs $909K.
- CEO cites sales initiatives paying off; VP of Sales highlights competitive advantage in food safety.
- Business update stresses customer focus, IoT/SaaS innovation, and 100 years of combined staff experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006028/000149315223044855/0001493152-23-044855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006028/000149315223044855/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-044855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer